GetTopicDetailResponse(id=cdf7109028dd, topicName=佩米替尼, introduction=佩米替尼, content=非小細(xì)胞肺癌 佩米替尼, image=null, comments=0, allHits=834, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Fri Dec 22 14:57:54 CST 2023, time=2023-12-22, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=484885, tagList=[TagDto(tagId=484885, tagName=佩米替尼)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2176553, encodeId=0b6721e655312, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=cdf7109028dd' target=_blank style='color:#2F92EE;'>#佩米替尼#</a>, objectTitle=首例：佩米替尼做為FGFR變異晚期NSCLC的二線(xiàn)或后線(xiàn)治療顯示長(zhǎng)期臨床獲益, objectType=article, longId=806488, objectId=312d80648815, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-researcher-explores-new-medicine-D5BGJES.jpg, objectUrl=/article/show_article.do?id=312d80648815, replyNumber=0, likeNumber=107, createdTime=2023-12-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=312d80648815, moduleTitle=首例：佩米替尼做為FGFR變異晚期NSCLC的二線(xiàn)或后線(xiàn)治療顯示長(zhǎng)期臨床獲益, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=312d80648815)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2023-12-22發(fā)表于上海
